DE602004022423D1 - Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz - Google Patents

Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Info

Publication number
DE602004022423D1
DE602004022423D1 DE602004022423T DE602004022423T DE602004022423D1 DE 602004022423 D1 DE602004022423 D1 DE 602004022423D1 DE 602004022423 T DE602004022423 T DE 602004022423T DE 602004022423 T DE602004022423 T DE 602004022423T DE 602004022423 D1 DE602004022423 D1 DE 602004022423D1
Authority
DE
Germany
Prior art keywords
insulin resistance
inhibition
treatment
kinase activity
kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004022423T
Other languages
English (en)
Inventor
Johan Auwerx
Francesca Frigerio
Stefano Fumagalli
Sara Kozma
Frederic Picard
Melanie Sticker-Jantscheff
George Thomas
Sung Hee Um
Mitsuhiro Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Original Assignee
Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Novartis Forschungsstiftung
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research, Novartis Forschungsstiftung filed Critical Novartis Forschungsstiftung Zweigniederlassung Friedrich Miescher Institute for Biomedical Research
Publication of DE602004022423D1 publication Critical patent/DE602004022423D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Public Health (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Endocrinology (AREA)
DE602004022423T 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz Active DE602004022423D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49722603P 2003-08-22 2003-08-22
PCT/EP2004/009368 WO2005019829A1 (en) 2003-08-22 2004-08-20 Inhibition of s6 kinase activity for the treatment of insulin resistance

Publications (1)

Publication Number Publication Date
DE602004022423D1 true DE602004022423D1 (de) 2009-09-17

Family

ID=34216100

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004022423T Active DE602004022423D1 (de) 2003-08-22 2004-08-20 Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz

Country Status (7)

Country Link
US (1) US20070191259A1 (de)
EP (1) EP1658504B1 (de)
JP (1) JP2007503203A (de)
AT (1) ATE438859T1 (de)
DE (1) DE602004022423D1 (de)
ES (1) ES2331006T3 (de)
WO (1) WO2005019829A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006020755A2 (en) * 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
EP2397563A3 (de) * 2004-09-17 2012-07-18 Isis Pharmaceuticals, Inc. Verbesserte Antisense-Oligonukleotide
US7897595B2 (en) * 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
CN110898225A (zh) * 2019-12-23 2020-03-24 黑龙江中医药大学 mTOR/S6K1及MAPK信号通路抑制在胰岛素抵抗改善中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US20030083284A1 (en) * 2001-08-01 2003-05-01 Isis Pharmaceuticals Inc. Antisense modulation of p70 S6 kinase expression
EP1234188A2 (de) * 1999-12-02 2002-08-28 The University of Dundee Protein kinase regulierung
GB0224338D0 (en) * 2002-10-18 2002-11-27 Novartis Forschungsstiftung Modulation of S6 kinase activity for the treatment of obesity

Also Published As

Publication number Publication date
JP2007503203A (ja) 2007-02-22
ES2331006T3 (es) 2009-12-18
EP1658504B1 (de) 2009-08-05
WO2005019829A1 (en) 2005-03-03
US20070191259A1 (en) 2007-08-16
EP1658504A1 (de) 2006-05-24
ATE438859T1 (de) 2009-08-15

Similar Documents

Publication Publication Date Title
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE602004017736D1 (de) Verwendung von rapamycin und dessen derivaten zur behandlung von knochenverlust
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
ATE553086T1 (de) Substituierte heterocyclische verbindungen und deren verwendung zur behandlung der multipler medikamentenresistenz
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
DE60222302D1 (de) Inhibitoren von mitotischem kinesin
ATE354563T1 (de) Sulfonderivate zur hemmung von gamma-secretase
ATE548354T1 (de) Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
DE60312516D1 (de) Inhibitoren von mitotischem kinesin
MY140132A (en) Thiazolidin-4-one derivatives for use in the treatment of anemias
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE497763T1 (de) Verfahren und reagenzien zur behandlung von entzündlichen erkrankungen
MX2010000956A (es) Derivados de isoftalamida que inhiben actividad de beta-secretasa.
DE602004004883D1 (de) Vegf-antagonisten zur behandlung von diabetes
ATE332688T1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
DE602004022423D1 (de) Hemmung der s6-kinase-aktivität zur behandlung von insulinresistenz
ATE549026T1 (de) Verwendung von pinitol zur behandlung von leberkrankheiten in säugetieren
DE60137721D1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE267194T1 (de) Medikamente geeignet zur behandlung von proliferativen erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
ATE427754T1 (de) Verwendung von il-17f zur behandlung und/oder pravention von neurologischen erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN